Antonella Perotti
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
Bauer T, Santoro A, Lin C, Garrido-Laguna I, Jörger M, Greil R, Spreafico A, Yau T, Goebeler M, Hütter-Krönke M, Perotti A, Juif P, Lu D, Barys L, Cremasco V, Pelletier M, Evans H, Fabre C, Doi T. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors. J Immunother Cancer 2023; 11
29.11.2023Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
29.11.2023J Immunother Cancer 2023; 11
Bauer Todd M, Santoro Armando, Lin Chia-Chi, Garrido-Laguna Ignacio, Jörger Markus, Greil Richard, Spreafico Anna, Yau Thomas, Goebeler Maria-Elisabeth, Hütter-Krönke Marie Luise, Perotti Antonella, Juif Pierre-Eric, Lu Darlene, Barys Louise, Cremasco Viviana, Pelletier Marc, Evans Helen, Fabre Claire, Doi Toshikiko
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine
Perotti A, Haluska F, Rivera V, Berk L, Corradino I, Marsoni S, Albanell J, Rojo F, Cresta S, Cerny T, Maur M, Capri G, Viganò L, Hess D, Sessa C, Locatelli A, Gianni L. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol 2010; 28:4554-61.
20.09.2010Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine
20.09.2010J Clin Oncol 2010; 28:4554-61
Perotti Antonella, Haluska Frank, Rivera Victor M, Berk Lori, Corradino Irene, Marsoni Silvia, Albanell Joan, Rojo Federico, Cresta Sara, Cerny Thomas, Maur Michela, Capri Giuseppe, Viganò Lucia, Hess Dagmar, Sessa Cristiana, Locatelli Alberta, Gianni Luca